Skip to main content

Table 3 Outcomes for survivors

From: Azithromycin in the extremely low birth weight infant for the prevention of Bronchopulmonary Dysplasia: a pilot study

  Azithromycin Group
(n = 14)
Placebo Group
(n = 12)
p-value
Incidence of BPD-no. (%) 9 (64.3) 10 (83.3) 0.26
Duration of Mechanical Ventilation-median (range) 13 (1–47) 35 (1–112) 0.02
Postnatal-steroid 3 (18.8) 8 (66.7) 0.02
Days of CPAP (range) 8 ± 7 8 ± 6 0.98
Grade III or IV IVH-no. (%) 2 (14) 2 (16) 0.86
PVL on HUS-no. (%) 1 (7) 2 (16) 0.58
Abnormal Transaminases (AST) 0 1 (8) 0.46
Bilirubin Peak 6.9 ± 1.8 6.4 ± 2.1 0.54
Days to full feeds‡ 17 ± 5 18 ± 4 0.76
Feeding intolerance*-no. (%) 4 (29) 7 (58) 0.12
Necrotizing Enterocolitis-no. (%) 0 1 (8) 0.46
Abnormal hearing screen-no. (%) 0 3 (25) 0.08
Bacterial Infection:    
Blood-no. (%) 8 (57) 5 (42) 0.43
Urine-no. (%) 0 3 (25) 0.08
CSF-no. (%) 0 2 (17) 0.20
Fungal Infection:    
Blood-no. (%) 2 (14) 1 (8) 1.0
Urine-no. (%) 0 1 (8) 0.46
CSF-no. (%) 1 (7) 0 1.0
Days of Antibiotics§ 12 ± 11 24 ± 23 0.09
Caffeine Therapy-no. (%) 13 (92) 10 (83) 0.58
PDA†-no. (%) 7 (50) 9 (75.0) 0.18
Indomethacin¥    
Median 1 1 0.48
Interquartile range 0–1 0–2  
PDA ligated-no. (%) 3 (21) 3 (25) 0.82
Diuretics-no. (%) 5 (35) 7 (58) 0.24
Days of Diuretics 12 ± 25 28 ± 42 0.23
Bronchodilators-no. (%) 4 (28) 8 (67) 0.05
Days of Bronchodilators 7 ± 15 24 ± 25 0.04
Hospital days 77 ± 15 101 ± 32 0.02
  1. All data analysis was performed using ANOVA (mean ± sd), except for apgar scores and days of mechanical ventilation, which analyzed using median test. *Defined as feeds being held for more than 24 hours, while on study. †Confirmed by echocardiogram. ‡Defined as when TPN was discontinued. §Excluding azithromycin. ¥Performed using wilcoxon rank sum test.